JPWO2023009759A5 - - Google Patents

Info

Publication number
JPWO2023009759A5
JPWO2023009759A5 JP2024505116A JP2024505116A JPWO2023009759A5 JP WO2023009759 A5 JPWO2023009759 A5 JP WO2023009759A5 JP 2024505116 A JP2024505116 A JP 2024505116A JP 2024505116 A JP2024505116 A JP 2024505116A JP WO2023009759 A5 JPWO2023009759 A5 JP WO2023009759A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
amino
aryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024505116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529466A (ja
JP2024529466A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/038730 external-priority patent/WO2023009759A2/en
Publication of JP2024529466A publication Critical patent/JP2024529466A/ja
Publication of JP2024529466A5 publication Critical patent/JP2024529466A5/ja
Publication of JPWO2023009759A5 publication Critical patent/JPWO2023009759A5/ja
Pending legal-status Critical Current

Links

JP2024505116A 2021-07-30 2022-07-28 抗体薬物コンジュゲート及びその使用方法 Pending JP2024529466A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163227666P 2021-07-30 2021-07-30
US63/227,666 2021-07-30
US202263322914P 2022-03-23 2022-03-23
US63/322,914 2022-03-23
US202263344932P 2022-05-23 2022-05-23
US63/344,932 2022-05-23
PCT/US2022/038730 WO2023009759A2 (en) 2021-07-30 2022-07-28 Antibody-drug conjugates and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2024529466A JP2024529466A (ja) 2024-08-06
JP2024529466A5 JP2024529466A5 (https=) 2025-08-05
JPWO2023009759A5 true JPWO2023009759A5 (https=) 2025-08-05

Family

ID=85088249

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024505116A Pending JP2024529466A (ja) 2021-07-30 2022-07-28 抗体薬物コンジュゲート及びその使用方法
JP2024505498A Pending JP2024529506A (ja) 2021-07-30 2022-07-28 ネクチン－４に特異的な抗体および抗体複合体、並びにそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024505498A Pending JP2024529506A (ja) 2021-07-30 2022-07-28 ネクチン－４に特異的な抗体および抗体複合体、並びにそれらの使用方法

Country Status (9)

Country Link
US (2) US20250101098A1 (https=)
EP (3) EP4377319A2 (https=)
JP (2) JP2024529466A (https=)
KR (2) KR20240040098A (https=)
AU (2) AU2022320714A1 (https=)
CA (2) CA3227844A1 (https=)
IL (1) IL310432A (https=)
MX (2) MX2024001396A (https=)
WO (3) WO2023009759A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023009759A2 (en) * 2021-07-30 2023-02-02 R.P. Scherer Technologies, Llc Antibody-drug conjugates and methods of use thereof
KR20250161707A (ko) * 2024-05-08 2025-11-18 아주대학교산학협력단 Nectin-2에 결합하는 항체 약물 접합체 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2682449C2 (ru) * 2012-09-19 2019-03-19 Иннейт Фарма Связывающие kir3dl2 агенты
US9310374B2 (en) * 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
WO2015081282A1 (en) * 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
KR102783230B1 (ko) * 2015-11-09 2025-03-19 알.피.쉐러 테크놀러지즈 엘엘씨 항-cd22 항체-메이탄신 콘쥬게이트 및 그것의 사용 방법
IL269488B2 (en) * 2017-03-21 2023-09-01 Peptron Inc Conjugation of an antibody specifically for muc1 and its use
WO2019113248A1 (en) * 2017-12-07 2019-06-13 The Regents Of The University Of California Anti-upar antibody-drug conjugates and methods of use thereof
CA3082912A1 (en) * 2017-12-11 2019-06-20 Triphase Accelerator U.S. Corporation Anti-cd22 antibody-maytansine conjugates, combinations, and methods of use thereof
EP3740502A1 (en) * 2018-01-15 2020-11-25 Stichting Sanquin Bloedvoorziening Factor h potentiating antibodies and uses thereof
KR102892725B1 (ko) * 2018-05-09 2025-12-01 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 인간 넥틴4에 특이적인 항체
CN113874046B (zh) * 2019-01-23 2025-02-28 R.P.谢勒技术有限责任公司 用于抗体-药物缀合物的含有糖苷的肽接头
WO2023009759A2 (en) * 2021-07-30 2023-02-02 R.P. Scherer Technologies, Llc Antibody-drug conjugates and methods of use thereof

Similar Documents

Publication Publication Date Title
JP7403507B2 (ja) 薬物としてアマトキシンの誘導体を有する抗体薬物コンジュゲート
TW316905B (https=)
JP2019142870A5 (https=)
JP2015524796A5 (ja) 細胞毒性剤と細胞結合受容体との共役体
JP6117921B2 (ja) 細胞毒性剤と細胞結合受容体との共役体
EP3250238B1 (en) Antibody drug conjugates
DK2678037T3 (en) Branched linker for protein pharmaceutical conjugates
NZ302267A (en) Poly[pyrrolecarboxamido]naphthalenic acid derivatives; preparation and medicaments
JP2023010733A (ja) γ－アマニチンの誘導体
KR20160142885A (ko) 친화성 약제 컨쥬게이트
RU2009121626A (ru) Соединения агонисты рецептора глюкагоноподобного белка-1 (glp-1r)
AU619614B2 (en) Antibody-drug conjugates
JP2017529322A (ja) ポリオキサゾリン抗体薬物複合体
Yang et al. Convergent synthesis of hydrophilic monomethyl dolastatin 10 based drug linkers for antibody–drug conjugation
JPWO2022207699A5 (https=)
JPWO2023009759A5 (https=)
US20090325894A1 (en) Tetracyclic anthraquinones possessing anti-cancer properties
US20120308646A1 (en) Tetracyclic anthraquinones possessing anti-cancer properties
WO2011019942A2 (en) Synthetic cholesterylamine-linker derivatives for agent delivery into cells
JPWO2020154437A5 (https=)
JP2017160205A (ja) 細胞毒性剤と細胞結合受容体との共役体
WO2019181984A1 (ja) 分岐型単分散ポリエチレングリコール、中間体およびその製造方法
RU2024101910A (ru) Конъюгаты антитела и лекарственного средства и способы их использования
JPWO2022187370A5 (https=)
JPWO2021067458A5 (https=)